May 17, 2021

Seroconversion Rates Following COVID-19 Vaccination amongst Patients with Malignant Disease- the Impact of Diagnosis and Cancer-Directed Therapies

Category: Article Summary

Topic: Vaccines and Immunity

Keywords (Tags): cancer, vaccine

• [Pre-print, not peer-reviewed] Among patients with cancer (n = 201) who were fully vaccinated with the Pfizer-BioNTech, Moderna, or Johnson & Johnson/Janssen vaccines, the majority (94%) showed seroconversion for anti-spike protein IgG. Lower seroconversion frequencies were observed for patients with hematological malignancies (85%), particularly recipients of anti-CD20 therapies (70%) and stem cell transplantation (74%), compared to patients with solid organ tumors (98%). Patients receiving immune checkpoint inhibitor therapy (97%) or hormonal therapies (100%) also had high seroconversion. Overall, IgG titers were higher among those who received mRNA vaccines.

Thakkar et al. (May 14, 2021). Seroconversion Rates Following COVID-19 Vaccination amongst Patients with Malignant Disease- the Impact of Diagnosis and Cancer-Directed Therapies. Pre-print downloaded May 17 from https://doi.org/10.1101/2021.05.07.21256824